Trials / Completed
CompletedNCT01131546
Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,080 (estimated)
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levamlodipine besylate | Once daily, 7AM - 10AM |
| DRUG | Amlodipine maleate | Once daily, 7AM - 10AM |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-05-27
- Last updated
- 2011-06-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01131546. Inclusion in this directory is not an endorsement.